HomeCompareDZSI vs PFE

DZSI vs PFE: Dividend Comparison 2026

DZSI yields 9569.38% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DZSI wins by $35737885031950088.00M in total portfolio value
10 years
DZSI
DZSI
● Live price
9569.38%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35737885031950088.00M
Annual income
$35,018,028,809,619,510,000,000.00
Full DZSI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DZSI vs PFE

📍 DZSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDZSIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DZSI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DZSI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DZSI
Annual income on $10K today (after 15% tax)
$813,397.13/yr
After 10yr DRIP, annual income (after tax)
$29,765,324,488,176,583,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DZSI beats the other by $29,765,324,488,176,583,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DZSI + PFE for your $10,000?

DZSI: 50%PFE: 50%
100% PFE50/50100% DZSI
Portfolio after 10yr
$17868942515975044.00M
Annual income
$17,509,014,404,809,756,000,000.00/yr
Blended yield
97.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DZSI
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Price Target
$15.67
+74876.1% upside vs current
Range: $4.00 — $25.00
Altman Z
-2.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DZSI buys
0
PFE buys
0
No recent congressional trades found for DZSI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDZSIPFE
Forward yield9569.38%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$35737885031950088.00M$49.6K
Annual income after 10y$35,018,028,809,619,510,000,000.00$26,258.71
Total dividends collected$35689948118875920.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$15.67$27.50

Year-by-year: DZSI vs PFE ($10,000, DRIP)

YearDZSI PortfolioDZSI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$967,638$956,937.80$9,153$693.39+$958.5KDZSI
2$87,574,549$86,539,176.23$8,593$849.25+$87.57MDZSI
3$7,413,417,918$7,319,713,150.80$8,336$1,066.78+$7413.41MDZSI
4$587,028,750,175$579,096,393,002.64$8,437$1,384.80+$587028.74MDZSI
5$43,483,759,312,216$42,855,638,549,529.19$9,013$1,875.40+$43483759.30MDZSI
6$3,013,352,447,497,986$2,966,824,825,033,914.00$10,306$2,680.72+$3013352447.49MDZSI
7$195,370,121,665,113,570$192,145,834,546,290,720.00$12,820$4,101.38+$195370121665.10MDZSI
8$11,851,791,756,393,214,000$11,642,745,726,211,540,000.00$17,673$6,826.70+$11851791756393.20MDZSI
9$672,762,824,608,021,700,000$660,081,407,428,681,000,000.00$27,543$12,591.86+$672762824608021.75MDZSI
10$35,737,885,031,950,090,000,000$35,018,028,809,619,510,000,000.00$49,560$26,258.71+$35737885031950088.00MDZSI

DZSI vs PFE: Complete Analysis 2026

DZSIStock

DZS Inc. provides broadband network access solutions and communications platforms in the Americas, Europe, the Middle East, Africa, and Asia. It offers broadband connectivity solutions through DZS Velocity, including voice, high-definition and ultra-high-definition video, highspeed internet access, and business class services; switching and routing products; and XCelerate for increasing the velocity with which service providers can leap to multi-gigabit services. The company also provides connected home and business solutions through DZS Helix comprising smart gateway platforms for fiber to the x (FTTx) deployment; and connected premises products, consisting of indoor/outdoor optical network terminal gateways. In addition, it offers mobile and optical edge solutions through DZS Chronos, which provides solutions for mobile operators that enables them to upgrade their mobile fronthaul/midhaul/backhaul systems and migrate to fifth generation wireless technologies. Further, the company provides cloud software solutions through DZS Cloud that offers a commercial, carrier-grade network-slicing enabled orchestration platform, which supports open RAN and 4G/5G networks. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc. in August 2020. The company was founded in 1996 and is based in Plano, Texas.

Full DZSI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DZSI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DZSI vs SCHDDZSI vs JEPIDZSI vs ODZSI vs KODZSI vs MAINDZSI vs JNJDZSI vs MRKDZSI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.